Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation
Source abstract
Abstract
The advent of mRNA vaccines represents a breakthrough in the realm of cancer therapy and the prevention of infectious disease. Nevertheless, traditional lipid nanoparticle (LNP)-based mRNA vaccines can accumulate in the liver post-intramuscular injection, posing a risk of hepatotoxicity and reducing efficacy. Here we develop an albumin-recruiting LNP system with high lymphatic drainage and no accumulation in hepatic tissue to potentiate the efficacy and safety of mRNA vaccines. We construct a library of ionizable lipids with albumin-binding capacity as alternatives to traditional polyethylene-glycol-conjugated lipid. We identify an Evans blue-modified lipid-based LNP (EB-LNP) formulation that shows high in vivo expression, albumin-facilitated transport through intramuscular lymphatic vessels to the lymph nodes, high internalization by dendritic cells and low penetration into intramuscular blood vessels, thereby avoiding liver accumulation. EB-LNP-based mRNA vaccines demonstrate excellent antitumour and antiviral efficacy, resulting in strong cellular and humoral immune responses, including the robust activation of cytotoxic T lymphocytes and production of neutralizing antibodies post-vaccination. Overall, this system shows promise as an effective and minimally toxic platform for the development of mRNA vaccines with high efficacy and safety.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Hepatitis B Virus Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Pardi, N. et al. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).10.1038/nrd.2017.243 ↗
2. Hou, X. et al. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
3. Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases—advances, challenges and opportunities. Nat. Rev. Drug. Discov. 23, 838–861 (2024).10.1038/s41573-024-01042-y ↗
4. Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135–136 (2023).10.1038/s41577-022-00825-x ↗
5. Chen, J. et al. Current developments and challenges of mRNA vaccines. Annu. Rev. Biomed. Eng. 24, 85–109 (2022).10.1146/annurev-bioeng-110220-031722 ↗
6. Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024).10.1016/S0140-6736(23)02268-7 ↗
7. Ndeupen, S. et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).10.1016/j.isci.2021.103479 ↗
8. Pateev, I. et al. Biodistribution of RNA vaccines and of their products: evidence from human and animal studies. Biomedicines 12, 59 (2023).10.3390/biomedicines12010059 ↗
9. Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316–1327 (2017).10.1016/j.ymthe.2017.03.035 ↗
10. Ye, Z. et al. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proc. Natl Acad. Sci. USA 120, e2311752120 (2023).
11. Shi, Y. et al. Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses. Sci. Adv. 8, eabo1827 (2022).10.1126/sciadv.abo1827 ↗
12. Chen, J. et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc. Natl Acad. Sci. USA 119, e2207841119 (2022).
13. Kitagawa, H. et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. J. Infect. Chemother. 28, 576–581 (2022).10.1016/j.jiac.2021.12.034 ↗
14. Schinas, G. et al. Immune-mediated liver injury following COVID-19 vaccination. World J. Virol. 12, 100–108 (2023).10.5501/wjv.v12.i2.100 ↗
15. Efe, C. et al. Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology 76, 1576–1586 (2022).10.1002/hep.32572 ↗
16. Boettler, T. et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J. Hepatol. 77, 653–659 (2022).10.1016/j.jhep.2022.03.040 ↗
17. Zin Tun, G. S. et al. Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. J. Hepatol. 76, 738–753 (2022).10.1016/j.jhep.2021.09.031 ↗
18. Jeong, M. et al. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. Adv. Drug Deliv. Rev. 200, 114990 (2023).10.1016/j.addr.2023.114990 ↗
19. Liu, M. et al. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy. Sci. Adv. 10, eadk2444 (2024).10.1126/sciadv.adk2444 ↗
20. Sasaki, K. et al. mRNA-loaded lipid nanoparticles targeting dendritic cells for cancer immunotherapy. Pharmaceutics 14, 1572 (2022).10.3390/pharmaceutics14081572 ↗
21. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).10.1038/s41565-020-0669-6 ↗
22. Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing. Nat. Mater. 20, 701–710 (2021).10.1038/s41563-020-00886-0 ↗
23. Yu, X. et al. Poly(ethyl ethylene phosphate): overcoming the ‘polyethylene glycol dilemma’ for cancer immunotherapy and mRNA vaccination. ACS Nano 17, 23814–23828 (2023).10.1021/acsnano.3c07932 ↗
24. Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188, 114416 (2022).10.1016/j.addr.2022.114416 ↗
25. Tenchov, R. et al. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug. Chem. 34, 941–960 (2023).10.1021/acs.bioconjchem.3c00174 ↗
26. Dilliard, S. A. et al. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e210925611 (2021).10.1073/pnas.2109256118 ↗
27. Elzoghby, A. O. et al. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release 157, 168–182 (2012).10.1016/j.jconrel.2011.07.031 ↗
28. Abdallah, M. et al. Lymphatic targeting by albumin-hitchhiking: applications and optimisation. J. Control. Release 327, 117–128 (2020).10.1016/j.jconrel.2020.07.046 ↗
29. Famta, P. et al. Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics. J. Control. Release 353, 166–185 (2022).10.1016/j.jconrel.2022.11.034 ↗
30. Qi, S. et al. The bright future of nanotechnology in lymphatic system imaging and imaging-guided surgery. J. Nanobiotechnol. 20, 24 (2022).10.1186/s12951-021-01232-5 ↗
31. Zhu, G. et al. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat. Commun. 8, 1954 (2017).
32. Um, W. et al. A comparative study on albumin-binding molecules for targeted tumor delivery through covalent and noncovalent approach. Bioconjug. Chem. 30, 3107–3118 (2019).10.1021/acs.bioconjchem.9b00760 ↗
33. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519–522 (2014).10.1038/nature12978 ↗
34. Song, Y. et al. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. Sci. Transl. Med. 14, eabl3649 (2022).10.1126/scitranslmed.abl3649 ↗
35. Lin, T. et al. Blood–brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano 10, 9999–10012 (2016).10.1021/acsnano.6b04268 ↗
36. Liu, Z. & Chen, X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem. Soc. Rev. 45, 1432–1456 (2016).10.1039/C5CS00158G ↗
37. Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595, 572–577 (2021).10.1038/s41586-021-03653-6 ↗
38. Liu, Y. et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat. Nanotechnol. 17, 206–216 (2022).10.1038/s41565-021-01032-w ↗
39. Bern, M. et al. The role of albumin receptors in regulation of albumin homeostasis: implications for drug delivery. J. Control. Release 211, 144–162 (2015).10.1016/j.jconrel.2015.06.006 ↗
40. Ishima, Y. et al. The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors. Chem. Pharm. Bull. 70, 330–333 (2022).10.1248/cpb.c21-01024 ↗
41. Wan, Y. et al. Stable organic photosensitizer nanoparticles with absorption peak beyond 800 nanometers and high reactive oxygen species yield for multimodality phototheranostics. ACS Nano 14, 9917–9928 (2020).10.1021/acsnano.0c02767 ↗
42. Sindhwani, S. et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566–575 (2020).10.1038/s41563-019-0566-2 ↗
43. Nguyen, L. N. M. et al. The exit of nanoparticles from solid tumours. Nat. Mater. 22, 1261–1272 (2023).10.1038/s41563-023-01630-0 ↗
44. Embgenbroich, M. & Burgdorf, S. Current concepts of antigen cross-presentation. Front. Immunol. 9, 1643 (2018).10.3389/fimmu.2018.01643 ↗
45. Oğuz, F. & Atmaca, H. mRNA as a therapeutics: understanding mRNA vaccines. Adv. Pharm. Bull. 12, 274–282 (2022).
46. Szymonowicz, K. A. & Chen, J. Biological and clinical aspects of HPV-related cancers. Cancer Biol. Med. 17, 864 (2020).10.20892/j.issn.2095-3941.2020.0370 ↗
47. Mirabello, L. et al. HPV16 E7 genetic conservation is critical to carcinogenesis. Cell 170, 1164–1174 (2017).10.1016/j.cell.2017.08.001 ↗
48. Feshchenko, E. et al. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMC Biotechnol. 12, 77 (2012).10.1186/1472-6750-12-77 ↗
49. Cyster, J. G. & Allen, C. D. C. B cell responses: cell interaction dynamics and decisions. Cell 177, 524–540 (2019).10.1016/j.cell.2019.03.016 ↗
50. De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137–148 (2015).10.1038/nri3804 ↗
51. Mittenbühler, M. J. et al. Isolation of extracellular fluids reveals novel secreted bioactive proteins from muscle and fat tissues. Cell Metab. 35, 535–549 (2023).10.1016/j.cmet.2022.12.014 ↗
52. Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896–910 (2014).10.1016/j.cell.2014.10.010 ↗